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1  | INTRODUC TION
Although	 still	 considered	a	novel	 technology,	 ex	vivo	perfusion	of	
recovered	organs	from	deceased	donors	is	likely	to	become	widely	
adopted in the near future.1,2	Ex	vivo	perfusion	offers	the	potential	
to	assess	 the	viability	of	organs	before	 transplantation,	and	to	ex‐
tend	 the	acceptable	period	between	 recovery	and	 implantation.	 It	
may	also	enable	targeting	of	the	isolated	organs	with	specific	thera‐
pies aimed at prolonging allograft survival.3 One particular focus of 
such	strategies	is	likely	to	be	donor‐derived	T	cell	populations	(naïve	
or	memory)	that	are	resident	within	the	graft.4,5
We	 have	 recently	 reported	 that	 passenger	 T	 cells	 are	 present	
within	human	donor	organs	recovered	for	transplantation	and,	using	
murine	 transplant	models,	have	demonstrated	 that	donor	T	effec‐





2  | MATERIAL S AND METHODS
2.1 | Identification of circulating donor CD4 T 
lymphocytes in human lung transplant recipients
Following	adult	deceased‐donor	 lung	or	heart	plus	 lung	transplan‐
tation,	 blood	 from	 consenting	 recipients	 was	 sampled	 at	 prede‐




clear	 cells	 (PBMCs)	 were	 labeled	 with	 anti‐CD3‐FITC	 (fluorescein	
isothiocyanate,	clone	HIT3a)	and	anti‐CD4	PE	(phycoerythrin,	clone	
RPA‐T4)	monoclonal	antibodies	(both	BD	Biosciences,	Oxford,	UK)	
and	with	 the	 relevant	MHC	 class	 I	HLA‐specific	 biotinylated	 anti‐
body	 that	were	 selected	 to	 bind	 exclusively	 to	 donor	 (but	 not	 re‐
cipient)	 HLA	 class	 I	 MHC	 alloantigen	 (see	 Table	 S1;	 kindly	 gifted	
by	 Prof.	 Frans	 Claas,	 Leiden	 University	 Medical	 Center,	 Leiden,	
the	Netherlands).	 Cells	were	 further	 labeled	with	 allophycocyanin	
(APC)–conjugated	 streptavidin	 (Invitrogen,	 Paisley,	UK)	 and	 donor	
cells	were	 identified	using	BD	FACSCantoTM	flow	cytometer	with	
BD	FACSDiva	software	(BD	Pharmingen,	Berkshire	UK).	Pure	pop‐
ulations	 of	 donor	 and	 recipient	CD4	T	 cells	 (obtained	 from	donor	
spleen/lymph	nodes	and	recipient	blood	before	transplantation,	re‐
spectively)	were	 used	 as	 positive	 and	 negative	 controls	 for	 donor	
lymphocyte	 identification.	 Positive	 identification	 of	 donor	 CD4	 T	
cells	 in	 test	 samples	was	based	on	 relative	 intensity	of	 staining	of	
control	donor	to	recipient	cells	(Figure	S1).
The	 human	 lung	 study	 received	 a	 favorable	 ethical	 opinion	 by	
the	Cambridgeshire	4	Research	Ethics	Committee	and	was	approval	
by	 the	Health	 Research	Authority.	 The	 study	was	 registered	with	
the	National	 Institute	of	Health	Research	 (NIHR)	Clinical	Research	
Network	Portfolio.
2.2 | Characterization of lymphocyte subsets 
released during ex vivo normothermic perfusion
Kidneys	 underwent	 1	 hour	 of	 normothermic	 machine	 perfu‐
sion,	 as	 described	 previously,7	 with	 a	 leukocyte	 filter,	 RS1VAE	
(Haemonetics,	Coventry,	UK),	in	the	circuit.	After	1	hour,	the	filter	
was	removed	and	flushed	in	an	antegrade	direction	with	400	mL	




lets	 were	 cryopreserved	 with	 10%	 DMSO	 (dimethyl	 sulfoxide)	
in	 fetal	 calf	 serum	 (FCS),	 and	 stored	 at	 −80°C.	 For	 flow	 cytom‐
etry	 characterization,	 cells	 were	 quickly	 thawed	 in	 Dulbecco′s	
Modified	Eagle′s	Medium	(Gibco,	D5030,	ThermoFisher	Scientific,	
UK)	 with	 2%	 FCS	 and	 resuspended	 in	 FACS	 buffer	 (PBS,	 1%	
FCS,	0.02%	sodium	azide).	Cells	were	stained	 in	FACS	buffer	for	
30	minutes	 on	 ice	with	 the	 following	 antibodies:	 PE	 anti‐human	
CD127	 (clone	 eBioRDR5,	ThermoFisher	 Scientific),	 Brilliant	Blue	




twice	with	 FACS	 buffer	 after	 antibody	 staining,	 and	 cell	 events	
were	 collected	 on	 FACSCanto	 II	 analyzers	 (BD	Pharmingen)	 and	
analyzed	with	 FlowJo	 software	 (FlowJo,	 LLC,	 Ashland,	OR).	 The	
human	kidney	study	had	received	favorable	ethical	approval	from	
Newcastle	&	North	 Tyneside	 2	Research	 Ethics	Committee	REC	
(15/NE/0408).
2.3 | Animals
C57BL/6J	 (H‐2b;	 B6)	 were	 purchased	 from	 Charles	 River	
Laboratories	 (Margate,	 UK).	 Bm12	 mice	 (B6(C)‐H2‐Ab1bm12/
KhEgJ	[H‐2bm12])	and	H‐2b	T	cell	receptor‐deficient	mice	(Tcrbd−/− 
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2.5 | Adoptive transfer of donor/recipient–derived 
nT‐regs
Recipient	B6	mice	were	adoptively	transferred	by	tail‐vein	 intra‐
venous	 injection	with	 1	×	106	 nT‐regs	 derived	 from	B6	 or	 bm12	
animals	on	 the	 first	postoperative	day	after	bm12	cardiac	 trans‐
plantation.	 nT‐regs	 were	 purified	 from	 spleens	 of	 naïve	 B6	 or	
bm12	 animals	 using	 the	 CD4+CD25+	 Regulatory	 T	 Cell	 Isolation	
Kit	 (Miltenyi	 Biotec,	 Auburn,	 CA)	 and	 an	 autoMACS	 separator	
(Miltenyi);	 cell	 purity	 (typically	 >90%	CD25+ve	 CD4+ve)	 was	 ana‐
lyzed	by	flow	cytometry	prior	to	injection.
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for	 comparison	 of	 antinuclear	 and	 anti‐vimentin	 autoantibody	 re‐





3.1 | Different CD4 T cell lineages are released from 
human allografts
Having	 previously	 demonstrated	 the	 presence	 of	 CD4	 T	 effector	
cells	 within	 human	 organs	 recovered	 for	 transplantation,6,12	 we	
sought	 to	 determine	whether	 donor	 CD4	 T	 cells,	 and	 specifically,	
donor	T‐regs,	could	potentially	also	be	released	into	the	recipient's	
circulation	 following	 transplantation.	 Human	 lung	 transplant	 re‐
cipients	 (n	=	21)	were	 therefore	 followed	 for	 the	 first	 year	 follow‐






1.54	±	1.41%).	Numbers	of	 cells	 recovered	were	 too	 small	 to	defi‐
nitely	assess	different	T	cell	lineages,	but	real‐time	polymerase	chain	





were	evident	 (Figure	1A):	 transient	 (detectable	 for	up	 to	6	weeks);	
intermediate	 (detectable	for	up	to	6	months);	or	persistent	 (lasting	
for	over	a	year).
The	 release	 of	 donor	 T‐regs	 was	 then	 assessed	 by	 analysis	
of	 leukocyte	 filters	 recovered	 from	human	 kidneys	 that	 had	 been	
obtained	 using	 standard	 recovery	 techniques,	 but	 then	 perfused	
normothermically	ex	vivo	using	 leukocyte‐depleted	blood.2	Hence	








sis	of	 the	stored	 leukocyte‐depleted	blood	used	 in	 the	circuit	 (not	
shown),	suggesting	that	the	T‐reg	population	had	been	released	on	
reperfusion	of	the	retrieved	kidneys.
3.2 | T‐reg depletion results in augmented humoral 







cells	by	passenger	donor	CD4	T	lymphocytes.6,12,13 In comparison to 
unmodified	WT	C57BL/6	recipients,	depletion	of	the	T‐reg	popula‐
tion	by	administration	of	anti‐CD25	mAb	to	C57BL/6	mice	at,	and	
following,	 transplantation	 with	 bm12	 (B6(C)‐H2‐Ab1bm12/KhEgJ)	
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3.3 | Donor‐derived T‐regs prolong allograft 
survival more effectively than recipient T‐regs
In	 the	 preceding	 experiments,	 anti‐CD25	 treatment	 of	 the	 recipi‐
ent	was	continued	after	transplantation,	raising	the	possibility	that	









F I G U R E  2  T‐reg	depletion	augments	


















is dependent on transfer of passenger 
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transferred	donor	T‐regs	were	also	targeted.	Notably,	 transplanta‐
tion of heart allografts from donor bm12 mice that had received 
anti‐CD25	treatment	before	organ	recovery	also	triggered	markedly	
augmented	autoantibody	responses	in	WT	C57BL/6	recipient	mice,	
and	 heart	 allografts	were	 rejected	 at	 least	 as	 rapidly	 as	 following	
recipient	T‐reg	depletion	(Figure	3A,B).	To	test	the	comparative	ef‐
ficacy	of	 donor	 versus	 recipient‐derived	T‐regs	 in	 preventing	 allo‐
graft	rejection,	WT	C57BL/6	recipients	of	unmodified	bm12	heart	









and,	 at	 least	 following	 lung	 transplantation,	may	 persist	 for	 some	
time.	 Within	 a	 larger	 population	 of	 conventional	 CD4	 T	 effector	
cells,	smaller	numbers	of	regulatory	T	cells	can	be	identified,	and	our	





It	 is	 perhaps	 surprising	 that	 donor‐derived	 nT‐regs	were	more	
effective	 than	 recipient‐derived	 nT‐regs	 at	 blocking	 host	 humoral	
responses.	 Although	 the	 precise	 target	 epitopes	 remain	 ill‐de‐
fined,16,17	nT‐regs	are	 thought	 to	 recognize	specific,	 self‐restricted	


















F I G U R E  3  Donor	T‐reg	depletion	
results	in	exacerbated	autoantibody	
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retain	donor	T‐regs	within	 the	 allograft,	 our	 results	 suggest	 that	
donor‐derived	T‐regs	may	hold	potential	as	a	cellular	 therapy	 for	
prolonging	 allograft	 survival.	 This	 would	 differ	 from	 strategies	
that	 are	 currently	 under	 evaluation	 clinically,	 and	 that	 typically	
employ	recipient‐derived	CD4	T‐regs	that	are	either	polyclonal	or	
exhibit	 direct	 allospecificity	 for	 the	 donor.31 In a similar fashion 
to	donor	effector	CD4	T	 cells	 (that	provide	promiscuous	help	 to	
all	 B	 cells	 engaging	 target	 antigen),	 transferred	 donor‐derived	T‐
regs	would	 be	 expected	 to	 inhibit	 host	 B	 cell	 responses	 against	
concurrently	 encountered	 alloantigen,	 even	 those	 alloantigens	
that	are	expressed	on	the	T‐reg	surface.6	Thus,	it	seems	probable	
that	 donor‐derived	 T‐regs	 will	 be	 effective	 in	 transplant	 models	
incorporating	 donor‐recipient	 strain	 combinations	 that	 are	 more	
MHC‐mismatched;	 certainly,	 direct‐pathway	 allorecognition	 of	
host	MHC	class	II	by	donor‐derived	T‐regs	is	likely	to	be	at	least	as	





either	 increasing	 the	proportion	of	T‐regs	within	 the	 transferred	
population	 that	 exhibit	 direct‐pathway	 allospecificity,	 or	 by	 first	
generating	memory	T‐regs	directed	against	intact	host	MHC	class	
II.32	 In	 this	 regard,	 it	 is	notable	 that	heart	allografts	 that	contain	
memory	CD4	T	cells	specific	for	host	MHC	class	II	(by	priming	the	
F I G U R E  4  Adoptive	transfer	of	donor	
nT‐reg	inhibits	recipient	autoantibody	































































































































differentiate/expand	 T‐regs	 with	 self‐restricted	 specificity	 for	 al‐






is,	 however,	 challenging,	 not	 least	 because	 the	 repertoire	 of	 pre‐
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